- Home
- PCK vs BDSX Comparison
PCK vs BDSX Comparison
Compare PCK & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCK
- BDSX
- Stock Information
- Founded
- PCK 2002
- BDSX 2005
- Country
- PCK United States
- BDSX United States
- Employees
- PCK N/A
- BDSX N/A
- Industry
- PCK Trusts Except Educational Religious and Charitable
- BDSX Precision Instruments
- Sector
- PCK Finance
- BDSX Health Care
- Exchange
- PCK Nasdaq
- BDSX Nasdaq
- Market Cap
- PCK 183.5M
- BDSX 215.3M
- IPO Year
- PCK N/A
- BDSX 2020
- Fundamental
- Price
- PCK $5.66
- BDSX $1.07
- Analyst Decision
- PCK
- BDSX Strong Buy
- Analyst Count
- PCK 0
- BDSX 4
- Target Price
- PCK N/A
- BDSX $3.08
- AVG Volume (30 Days)
- PCK 79.7K
- BDSX 318.9K
- Earning Date
- PCK 01-01-0001
- BDSX 02-28-2025
- Dividend Yield
- PCK 4.58%
- BDSX N/A
- EPS Growth
- PCK N/A
- BDSX N/A
- EPS
- PCK N/A
- BDSX N/A
- Revenue
- PCK N/A
- BDSX $65,562,000.00
- Revenue This Year
- PCK N/A
- BDSX $46.97
- Revenue Next Year
- PCK N/A
- BDSX $31.44
- P/E Ratio
- PCK N/A
- BDSX N/A
- Revenue Growth
- PCK N/A
- BDSX 48.92
- 52 Week Low
- PCK $4.85
- BDSX $1.07
- 52 Week High
- PCK $6.33
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- PCK 42.53
- BDSX 30.25
- Support Level
- PCK $5.50
- BDSX $1.09
- Resistance Level
- PCK $5.84
- BDSX $1.51
- Average True Range (ATR)
- PCK 0.07
- BDSX 0.10
- MACD
- PCK 0.00
- BDSX -0.04
- Stochastic Oscillator
- PCK 47.06
- BDSX 0.00
About PCK Pimco California Municipal Income Fund II of Beneficial Interest
PIMCO CA Muni Income Fund II is a closed-ended investment company. Its investment objective is to seek to provide current income exempt from federal and California income tax. The company portfolio of investment comprises of different sector investments such as healthcare, education, property, and others.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.